Siegfried successfully completes acquisition of an early-phase CDMO in
Wisconsin (US)
Siegfried AG / Key word(s): Acquisition
Siegfried successfully completes acquisition of an early-phase
CDMO in Wisconsin (US)
02.07.2024 / 06:30 CET/CEST
____________________________________________________________
Siegfried (SIX: SFZN) has completed the acquisition of an
early-phase CDMO site in Grafton, Wisconsin (US) from Curia
Global, strengthening Siegfried's customer offering for Drug
Substances in terms of capabilities and geography.
The acquisition was announced on June 12, 2024, and was completed
on July 1, 2024 with effect as of the same day.
Reto Suter, CEO ad interim and CFO of Siegfried: "We warmly
welcome our new Siegfried colleagues to our network. This
acquisition significantly enhances our early-stage development
services for Drug Substances, strengthens our geographical
coverage and will generate attractive opportunities. It will
further accelerate our growth story."
The acquisition reinforces Siegfried's position in the United
States, the world's largest pharmaceutical market. Siegfried
intends to develop the site into its Siegfried Acceleration Hub
for early-phase CDMO services to provide comprehensive support to
customers in the pre-clinical and clinical development and
manufacturing of Drug Substances. This further expands
Siegfried's offering, particularly for small and medium-sized
pharmaceutical companies. The focus on early-phase CDMO services
will fuel Siegfried's Drug Substance pipeline by capturing
additional attractive opportunities in their early stage,
creating significant growth opportunities in the future.
As part of the acquisition, all projects at the Grafton site have
been transferred to Siegfried and the Siegfried Acceleration Hub
will continue to fulfill all commitments to its existing
customers.
Contact
Financial Analysts: Media:
Dr. Reto Suter Peter Stierli
Chief Financial Officer Head Corporate Communications
reto.suter@siegfried.ch peter.stierli@siegfried.ch
Tel. +41 62 746 11 35 Tel. +41 62 746 15 51
Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
About Siegfried
The Siegfried Group is a global life sciences company with sites
in Switzerland, Germany, Spain, France, Malta, the USA and China.
In 2023, the company achieved sales of CHF 1.272 billion and
employed on 31.12.2023 more than 3700 people at twelve sites on
three continents. Siegfried Holding AG is publicly listed on the
SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in manufacturing pharmaceutical APIs (and
their intermediates) as well as drug products (tablets, capsules,
sterile vials, ampoules, cartridges and ointments) for the
pharmaceutical industry and provides development services.
Cautionary Statements Regarding Forward-Looking Statements
This media release includes statements concerning the future.
They are based on assumptions and expectations that may prove to
be wrong. They should be considered with due caution as, by
definition, they contain known and unknown risks, insecurities
and other factors which could result in a difference in the
actual results, financial situation, developments or the success
of Siegfried Holding AG or Siegfried Group from the explicit or
implicit assumptions made in these statements.
expect more
Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen, Switzerland
+41 62 746 11 11
info@siegfried.ch
www.siegfried.ch
____________________________________________________________
End of Media Release
____________________________________________________________
Language: English
Company: Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen
Switzerland
Phone: +41 62 746 11 11
E-mail: info@siegfried.ch
Internet: https://www.siegfried.ch
ISIN: CH0014284498
Listed: SIX Swiss Exchange
EQS News ID: 1936867
End of News EQS News Service
____________________________________________________________
1936867 02.07.2024 CET/CEST